Metabolic & Weight Management
5 compounds in this category.
5-Amino-1MQ
Unregulated5-amino-1-methylquinolinium, NNMT inhibitor
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism and …
Route
Oral
Dose
50–100 mg
Cycle
8–12 weeks
Cagrilintide
InvestigationalAM833, CagriSema (in combination with semaglutide)
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appet…
Route
SubQ (investigational)
Dose
2.4 mg (in combination trials)
Cycle
Ongoing — not commercially available
Survodutide
InvestigationalBI 456906, Boehringer Ingelheim dual agonist
A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/N…
Route
SubQ (investigational)
Dose
Up to 6.0 mg (in clinical trials)
Cycle
Ongoing — not commercially available
Pemvidutide
InvestigationalALT-801, Altimmune dual agonist
A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (M…
Route
SubQ (investigational)
Dose
1.8 mg or 2.4 mg (in clinical trials)
Cycle
Ongoing — not commercially available
Mazdutide
InvestigationalIBI362, LY3305677
A GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly. Mazdutide has shown strong weig…
Route
SubQ
Dose
6 mg or 9 mg (approved doses in China)
Cycle
Ongoing